IKZF1 and acute lymphoblastic leukemia: Adding imatinib to the therapy for patients with BCR-ABL1 fusion to strengthen the treatment of IKZF1-del patients can eliminate the adverse effect of IKZF1-del in contemporary ALL treatment (Yeoh et al., 2018).